Abstract: EZH2 is the catalytic subunit of polycomb repressive complex 2 (PRC2), which represses gene expression by catalyzing lysine 27 of histone H3. It is overexpressed in prostate cancer, breast cancer, bladder cancer, gastric cancer and several other cancers.There is a close correlation between overexpression of EZH2 and progression of malignancy, invasion and migration of cancer cells. With a thorough understanding of the function, up and down stream regulatory mechanism and clinicopathological features, EZH2 will be expected to as a target and provide a new way for the treatment of cancers.

Key words: color: green, font-family: "Times New Roman", mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-fareast-font-family: 宋体">Neoplasms, color: green, font-family: "Times New Roman", mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-fareast-font-family: 宋体, mso-font-kerning: 1.0pt">Therapy, color: green, font-family: "Times New Roman", mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-fareast-font-family: 宋体, mso-font-kerning: 1.0pt">EZH2